Related Experiment Video

Updated: Apr 21, 2026

Author Spotlight: Nuclei Isolation from Mouse Cardiac Progenitor Cells for Epigenome and Gene Expression Profiling at Single-Cell Resolution
10:03

Author Spotlight: Nuclei Isolation from Mouse Cardiac Progenitor Cells for Epigenome and Gene Expression Profiling at Single-Cell Resolution

Published on: May 12, 2023

4.2K

[The genome and cardiology]

Henning Bundgaard1, Birgitte Rode Diness, Jacob Tfelt-Hansen

  • 1Rigshospitalets Enhed for Arvelige Hjerte-sygdomme, Hjertecentret, Rigshospitalet, Blegdamsvej 9, 2100 København Ø. henningbundgaard@dadlnet.dk.

Ugeskrift for Laeger
|November 15, 2014
PubMed

Insights

Inherited cardiac diseases, like cardiomyopathies and arrhythmias, affect families. Genetic cascade screening identifies relatives at high risk, enabling targeted preventive care for sudden cardiac death.

Area of Science:

  • Cardiology
  • Genetics
  • Preventive Medicine

Background:

  • Autosomal dominant inheritance patterns are common in various cardiac conditions.
  • These include cardiomyopathies, channelopathies, dyslipidaemias, and aortic diseases.
  • Sudden cardiac death in young individuals is frequently linked to inherited cardiac diseases.

Purpose of the Study:

  • To highlight the significance of inherited cardiac diseases.
  • To emphasize the role of clinical and genetic cascade family screening.
  • To underscore the benefits of focused prophylaxis for high-risk relatives.

Main Methods:

  • Establishing a national network of cardiology centers.
  • Facilitating the sharing of patient pedigrees and clinical/genetic data.
  • Implementing systematic cascade screening protocols.

Main Results:

  • Identification of a national network for managing inherited cardiac diseases.
  • Centralized sharing of crucial patient and genetic information.
  • Enhanced ability to identify and manage high-risk family members.

Conclusions:

  • Cascade screening provides unique opportunities for early intervention.
  • Focused prophylaxis can be effectively delivered to at-risk relatives.
  • National collaboration improves the management of inherited cardiac diseases.

More Related Videos

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.2K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
889
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
814
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
17.3K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
108